Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 698

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

Open access
Hugosson, Jonas, Roobol, Monique J., Månsson, Marianne, Tammela, Teuvo L.J., Zappa, Marco, Nelen, Vera, Kwiatkowski, Maciej, Lujan, Marcos, Carlsson, Sigrid V., Talala, Kirsi M., Lilja, Hans, Denis, Louis J., Recker, Franz, Paez, Alvaro, Puliti, Donella, Villers, Arnauld, Rebillard, Xavier, Kilpeläinen, Tuomas P., Stenman, Ulf H., Godtman, Rebecka Arnsrud, Stinesen Kollberg, Karin, Moss, Sue M., Kujala, Paula, Taari, Kimmo, Huber, Andreas, van der Kwast, Theodorus, Heijnsdijk, Eveline A., Bangma, Chris, De Koning, Harry J., Schröder, Fritz H., Auvinen, Anssi·2019·European Urology

Abstract

Background: The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality. Objective: To determine whether PSA screening decreases PCa mortality for up to 16 yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended. Design, setting, and participants: This multicentre population-based randomised screening trial was conducted in eight European countries. Report includes 182 160 men, followed up until 2014 (maximum of 16 yr), with a predefined core age group of 162 389 men (55–69 yr), selected from population registry. Outcome measurements and statistical analysis: The outcome was PCa mortality, also assessed with adjustment for nonparticipation and the number of screening rounds attended. Results and limitations: The rate ratio of PCa mortality was 0.80 (95% confidence interval [CI] 0.72–0.89, p < 0.001) at 16 yr. The difference in absolute PCa mortality increased from 0.14% at 13 yr to 0.18% at 16 yr. The number of screening invitations needed to prevent one PCa death was 570 at 16 yr compared with 742 at 13 yr. The number needed to diagnose was reduced to 18 from 26 at 13 yr. Men with PCa detected during the first round had a higher prevalence of PSA >20 ng/ml (9.9% compared with 4.1% in the second round, p < 0.001) and higher PCa mortality (hazard ratio = 1.86, p < 0.001) than those detected subsequently. Conclusions: Findings corroborate earlier results that PSA screening significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up and a reduction in excess incidence. Repeated screening may be important to reduce PCa mortality on a population level. Patient summary: In this report, we looked at the outcomes from prostate cancer in a large European population. We found that repeated screening reduces the risk of dying from prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2019.02.009

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 698

Metadata

Authors
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Carlsson, S. V., Talala, K. M., Lilja, H., Denis, L. J., Recker, F., Paez, A., Puliti, D., Villers, A., Rebillard, X., Kilpeläinen, T. P., Stenman, U. H., Godtman, R. A., Stinesen Kollberg, K., Moss, S. M., Kujala, P., Taari, K., Huber, A., van der Kwast, T., Heijnsdijk, E. A., Bangma, C., De Koning, H. J., Schröder, F. H., & Auvinen, A.
Venue
European Urology
Publisher
Elsevier BV
Published
2019-07
Volume
76
Issue
1
Pages
43-51
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2916798133
Cited by
698
References
21
FWCI
45.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2019.02.009
The paper
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Carlsson, S. V., Talala, K. M., Lilja, H., Denis, L. J., Recker, F., Paez, A., Puliti, D., Villers, A., Rebillard, X., Kilpeläinen, T. P., Stenman, U. H., . . . Auvinen, A. (2019). A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2019.02.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.